Phase i trial of low dose decitabine targeting DNA hypermethylation in patients with chronic lymphocytic leukaemia and non-Hodgkin lymphoma: Dose-limiting myelosuppression without evidence of DNA hypomethylation

British Journal of Haematology

Volumn 150, Issue 2, 2010, Pages 189-195

  Blum, Kristie A ^a   Liu, Zhongfa ^b   Lucas, David M ^a,b   Chen, Ping ^b   Xie, Zhiliang ^b   Baiocchi, Robert ^a   Benson, Donald M ^a   Devine, Steven M ^a   Jones, Jeffrey ^a   Andritsos, Leslie ^a   Flynn, Joseph ^a   Plass, Christoph ^c   Marcucci, Guido ^a,b   Chan, Kenneth K ^a,b   Grever, Michael R ^a   Byrd, John C ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

chronic lymphocytic leukaemia; decitabine; methylation; non Hodgkin lymphoma

Indexed keywords

5 AZA 2' DEOXYCYTIDINE;

ADULT; AGED; AMMONIA BLOOD LEVEL; ANEMIA; ANOREXIA; ARTICLE; ASPERGILLUS PNEUMONIA; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER PAIN; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONFUSION; COUGHING; CULTURE NEGATIVE PNEUMONIA; DIARRHEA; DNA METHYLATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG FATALITY; DYSPNEA; EPIGENETICS; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GENE EXPRESSION; GENE SILENCING; HUMAN; HYPERBILIRUBINEMIA; HYPOTENSION; INFECTION; LOW DRUG DOSE; MALE; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; NEUTROPENIA; NONHODGKIN LYMPHOMA; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RELAPSE; SIDE EFFECT; SOMNOLENCE; STAPHYLOCOCCUS EPIDERMIS BACTEREMIA; STREPTOCOCCUS PNEUMONIA; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; DNA METHYLATION; DNA, NEOPLASM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; NEUTROPENIA; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 77954325193     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2010.08213.x     Document Type: Article

References (23)

1. Blum, W., Klisovic, R.B., Hackanson, B., Liu, Z., Liu, S., Devine, H., Vukosavljevic, T., Huynh, L., Lozanski, G., Kefauver, C., Plass, C., Devine, S.M., Heerema, N.A., Murgo, A., Chan, K.K., Grever, M.R., Byrd, J.C. Marcucci, G. (2007) Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. Journal of Clinical Oncology, 25, 3884 3891.
2. Blum, W., Klisovic, R., Liu, S., Garzon, R., Kefauver, C., Liu, Z., Mickle, J., Devine, H., Devine, S., Grever, M.R., Chan, K.K., Villalona-Calero, M., Byrd, J.C. Marcucci, G. (2008) Preliminary results of a phase II study of low dose decitabine as a single agent in older patients (age>=60) with previously untreated Acute Myeloid Leukemia (AML). Blood (ASH Annual Meeting Abstracts), 112, 2957.
3. Cheson, B.D., Bennett, J.M., Grever, M., Kay, N., Keating, M.J., O'Brien, S. Rai, K.R. (1996) National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood, 87, 4990 4997.
4. Cheson, B., Horning, S., Coiffier, B., Shipp, M., Fisher, R., Connors, J., Lister, T., Vose, J., Grillo-Lopez, A., Hagenbeek, A., Cabanillas, F., Klippensten, D., Hiddemann, W., Castellino, R., Harris, N., Armitage, J., Carter, W., Hoppe, R. Canellos, G. (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. Journal of Clinical Oncology, 17, 1244 1253.
5. Fernandez Calotti, P., Galmarini, C.M., Canones, C., Gamberale, R., Saenz, D., Avalos, J.S., Chianelli, M., Rosenstein, R. Giordano, M. (2008) Modulation of the human equilibrative nucleoside transporter1 (hENT1) activity by IL-4 and PMA in B cells from chronic lymphocytic leukemia. Biochemical Pharmacology, 75, 857 865.
6. Harris, N., Jaffe, E., Diebold, J., Flandrin, G., Muller-Hermelink, H., Vardiman, J., Lister, T. Bloomfield, C. (1999) World Health Organization classification of neoplastic disease of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee Meeting - Airlie House, Virginia, November 1997. Journal of Clinical Oncology, 17, 3835 3849.
7. Hubeek, I., Stam, R.W., Peters, G.J., Broekhuizen, R., Meijerink, J.P., van Wering, E.R., Gibson, B.E., Creutzig, U., Zwaan, C.M., Cloos, J., Kuik, D.J., Pieters, R. Kaspers, G.J. (2005) The human equilibrative nucleoside transporter 1 mediates in vitro cytarabine sensitivity in childhood acute myeloid leukaemia. British Journal of Cancer, 93, 1388 1394.
8. Issa, J.P., Garcia-Manero, G., Giles, F., Mannari, R., Thomas, D., Faderl, S., Bayar, E., Lyons, J., Rosenfeld, C., Cortes, J. Kantarjian, H. (2004) Phase I study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′deoxycytidine (decitabine) in hematopoietic malignancies. Blood, 103, 1635 1640.
9. Issa, J.P., Gharibyan, V., Cortes, J., Jelinek, J., Morris, G., Verstovsek, S., Talpaz, M., Garcia-Manero, G. Kantarjian, H.M. (2005) Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. Journal of Clinical Oncology, 23, 3948 3956. (Pubitemid 46218698)
10. Kantarjian, H., Oki, Y., Garcia-Manero, G., Huang, X., O'Brien, S., Cortes, J., Faderl, S., Bueso-Ramos, C., Ravandi, F., Estrov, Z., Ferrajoli, A., Wierda, W., Shan, J., Davis, J., Giles, F., Saba, H.I. Issa, J.P. (2007) Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood, 109, 52 57.
11. Katzenellenbogen, R.A., Baylin, S.B. Herman, J.G. (1999) Hypermethylation of the DAP-Kinase CpG island is a common alteration in B-Cell malignancies. Blood, 93, 4347 4353.
12. Liu, T.-H., Raval, A., Chen, S.-S., Matkovic, J.J., Byrd, J.C. Plass, C. (2006a) CpG island methylation and expression of the secreted frizzled-related protein gene family in chronic lymphocytic leukemia. Cancer Research, 66, 653 658.
13. Liu, Z., Marcucci, G., Byrd, J.C., Grever, M., Xiao, J. Chan, K.K. (2006b) Characterization of decomposition products and preclinical and low dose clinical pharmacokinetics of decitabine (5-aza-2′-deoxycytidine) by a new liquid chromatography/tandem mass spectrometry quantification method. Rapid Communications in Mass Spectrometry, 20, 1117 1126.
14. Liu, Z., Liu, S., Xie, Z., Blum, W., Perrotti, D., Paschka, P., Klisovic, R., Byrd, J., Chan, K.K. Marcucci, G. (2007) Characterization of in vitro and in vivo hypomethylating effects of decitabine in acute myeloid leukemia by a rapid, specific and sensitive LC-MS/MS method. Nucleic Acids Research, 35, e31.
15. Marce, S., Molina-Arcas, M., Villamor, N., Casado, F.J., Campo, E., Pastor-Anglada, M. Colomer, D. (2006) Expression of human equilibrative nucleoside transporter 1 (hENT1) and its correlation with gemcitabine uptake and cytotoxicity in mantle cell lymphoma. Haematologica, 91, 895 902.
16. Nakatsuka, S., Takakuwa, T., Tomita, Y., Hoshida, Y., Nishiu, M., Yamaguchi, M., Nishii, K., Yang, W.-I. Aozasa, K. (2003) Hypermethylation of death-associated protein (DAP) kinase CpG island is frequent not only in B-cell but also in T- and natural killer (NK)/T-cell malignancies. Cancer Science, 94, 87 91.
17. Qin, T., Jelinek, J., Si, J., Shu, J. Issa, J.P. (2009) Mechanisms of resistance to 5-aza-2′-deoxycytidine in human cancer cell lines. Blood, 113, 659 667.
18. Raval, A., Lucas, D.M., Matkovic, J.J., Bennett, K.L., Liyanarachchi, S., Young, D.C., Rassenti, L., Kipps, T.J., Grever, M.R., Byrd, J.C. Plass, C. (2005) TWIST2 demonstrates differential methylation in immunoglobulin variable heavy chain mutated and unmutated chronic lymphocytic leukemia. Journal of Clinical Oncology, 23, 3877 3885.
19. Raval, A., Tanner, S.M., Byrd, J.C., Angerman, E.B., Perko, J.D., Chen, S.-S., Hackanson, B., Grever, M.R., Lucas, D.M., Matkovic, J.J., Lin, T.S., Kipps, T.J., Murray, F., Weisenburger, D., Sanger, W., Lynch, J., Watson, P., Jansen, M., Yoshinaga, Y., Rosenquist, R., de Jong, P.J., Coggill, P., Beck, S., Lynch, H., de la Chapelle, A. Plass, C. (2007) Downregulation of death-associated protein kinase 1 (DAPK1) in chronic lymphocytic leukemia. Cell, 129, 879 890.
20. Rush, L.J., Raval, A., Funchain, P., Johnson, A.J., Smith, L., Lucas, D.M., Bembea, M., Liu, T.-H., Heerema, N.A., Rassenti, L., Liyanarachchi, S., Davuluri, R., Byrd, J.C. Plass, C. (2004) Epigenetic profiling in chronic lymphocytic leukemia reveals novel methylation targets. Cancer Research, 64, 2424 2433.
21. Stewart, D.J., Issa, J.P., Kurzrock, R., Nunez, M.I., Jelinek, J., Hong, D., Oki, Y., Guo, Z., Gupta, S. Wistuba, II (2009) Decitabine effect on tumor global DNA methylation and other parameters in a phase I trial in refractory solid tumors and lymphomas. Clinical Cancer Research, 15, 3881 3888.
22. Takahasi, T., Shivapurkar, N., Reddy, J., Shigematsu, H., Miyajima, K., Suzuki, M., Toyooka, S., Zochbauer-Muller, S., Drach, J., Parikh, G., Zheng, Y., Feng, Z., Kroft, S., Timmons, C., McKenna, R. Gazdar, A. (2004) DNA methylation profiles of lymphoid and hematopoietic malignancies. Clinical Cancer Research, 10, 2928 2935.
23. Yu, L., Liu, C., Vandeusen, J., Becknell, B., Dai, Z., Wu, Y.Z., Raval, A., Liu, T.H., Ding, W., Mao, C., Liu, S., Smith, L.T., Lee, S., Rassenti, L., Marcucci, G., Byrd, J., Caligiuri, M.A. Plass, C. (2005) Global assessment of promoter methylation in a mouse model of cancer identifies ID4 as a putative tumor-suppressor gene in human leukemia. Nature Genetics, 37, 265 274.